Skip to content

Psychiatria Polska

ISSN 2391-5854

12 papers in the library · 38 citations · publishing 2014-2026

Papers

Sort Most recent Most cited

Ketamine - mechanisms of action as an antidepressant

Psychiatria Polska April 30, 2026 Bronisław Gębik, Katarzyna Bliźniewska-Kowalska, Piotr Gałecki

Od 2000 roku ketamina i jej enancjomery są badane pod kątem swojego działania przeciwdepresyjnego. W niniejszej pracy zostanie krótko podsumowana droga ketaminy od anestetyku do leku przeciwdepresyjnego. W tekście przedstawione zostaną najważniejsze mechanizmy jej działania a także działania jej metabolitów. Praca ta ma na celu opisać rolę konkretnych grup receptorów w aktywacji istotnych...

Role of mycelia derived from in vitro cultures of Amanita spp. as a potential source of bioactive compounds with therapeutic potential for the mitigation and management of depressive disorders.

Psychiatria Polska October 31, 2025 Katarzyna Kała, Katarzyna Sułkowska‐ziaja, Joanna Piotrowska et al.

Mushrooms of the Amanita genus are considered among the most toxic, causing severe poisoning, often resulting in death. However, of the 707 described species within this genus, only around a dozen contain the toxic octapeptides classified as amanitotoxins and phallotoxins. While most representatives of the genus are considered inedible species, there are a few exceptions that are palatable...

Polish standard of treatment with racemic ketamine for patients with depressive disorders developed by a Working Group appointed by the National Consultant in the field of psychiatry.

Psychiatria Polska June 30, 2024 Piotr Gałecki, Katarzyna Maria Bliźniewska-Kowalska, Wiesław Jerzy Cubała et al. 5 citations

The Polish standard of treatment with racemic ketamine for patients with depressive disorders was developed by a Working Group appointed by the National Consultant in the field of psychiatry. Despite the wide range of available medications, as many as one-third of depressed patients do not respond to standard antidepressant treatment, raising the need for an ongoing search for new effective and...

The evolutionary and neurobiological attributes of consciousness: an update.

Psychiatria Polska June 30, 2024 Janusz Rybakowski, Filip Rybakowski

Consciousness is most frequently defined as a subjective experience of mental processes. The phenomenon of consciousness has always been a subject of great interest in various fields of science, including psychiatry, and the most prominent scientists have engaged in research on it. The studies performed in recent years have brought about novel data on the evolutionary and neurobiological...

DOI: 10.12740/PP/174391 (opens in new tab) Full text (opens in new tab) Evolution of consciousness Neurobiology of consciousness

Meditation and psychosis. The comparison of the current knowledge in the light of scientific evidence and the experience of an Eastern meditation teacher

Psychiatria Polska September 30, 2023 Marcel Baron, Agata Przybylska, Magdalena Justyna Piegza

The aim of the study was to compare the current knowledge on the relationship between the use of meditation techniques and the occurrence of psychosis with the experience of an Eastern meditation teacher, Osho Rajneesh. While searching the PubMed database using the keywords "meditation AND psychosis" 72 research articles were obtained, of which only 17 fully corresponded to the assumptions of...

Classical psychedelics in psychiatry - renaissance of interest and therapeutic perspectives.

Psychiatria Polska June 30, 2023 Askaniusz Jachimowski, Krzysztof Kucia

Substances that change the states of consciousness have been used in the therapeutics of traditional cultures for hundreds of years. In the Western cultural circle, scientific curiosity and hope for a breakthrough in the treatment of various mental disorders constituted the basis of the first wave of research on humans with the use of psychedelics. After synthesizing LSD, psychedelic substances...

DOI: 10.12740/PP/150053 (opens in new tab) Full text (opens in new tab) Pharmacotheraphy Psychedelics hallucinogens Entheogens Psychoactive drugs +4

Demographic and health characteristics of 3,4-methylenedioxymethamphetamine users (MDMA, ecstasy).

Psychiatria Polska October 31, 2022 Gniewko Więckiewicz, Dariusz Danel, Magdalena Piegza et al. 2 citations

MDMA is one of the most commonly used drugs in the world. Clinical studies are currently being conducted around the world on the use of this substance in the treatment of PTSD and alcoholism. However, little demographic information is available on users who use the substance for recreational purposes. The aim was to determine basic demographic and helath characteristics with validated tools....

Will MDMA-assisted psychotherapy become a breakthrough in treatment-resistant post-traumatic stress disorder? A critical narrative review.

Psychiatria Polska August 31, 2022 Sandra Szafoni, Gniewko Więckiewicz, Robert Pudło et al. 9 citations

Post-traumatic stress disorder (PTSD) is a common mental health condition that begins after exposure to a traumatic event. Despite recommended various therapeutic approaches, including both pharmacotherapy and psychotherapy, treatment is not as effective as expected. Over recent years the pharmaceutical industry has not been able to offer a new approach, founded on multiple mechanisms of...

Ayahuasca – potential therapeutic properties in psychiatry. Research review

Psychiatria Polska April 30, 2020 Aleksandra Barabasz-Gembczyk, Krzysztof Kucia 4 citations

Ayahuaska, zwana również „lianą duszy”, „pnączem duszy” to rytualny psychodelik podawany tradycyjnie w formie wywaru roślinnego, od stuleci stosowany przez rdzenną ludność Ameryki Południowej, a w ostatnich 25 latach również w krajach Europy, Azji, Afryki, Australii, w Kanadzie i Stanach Zjednoczonych Ameryki Północnej. Jej aktywność biologiczna wynika z zawartości N,N- dimetrylotryptaminy...

Schizophrenia as a disorder of embodied self

Psychiatria Polska April 30, 2018 Joanna Szczotka, Bartosz Majchrowicz 18 citations

Theories of schizophrenia propose numerous mechanisms underlying development of this disorder, yet the account including satisfactory etiological explanation is still lacking. Current trend is to indicate core, basic factors which may further give rise to whole diversity of symptoms. Experimental data and patients' reports show that such key factor may be selfexperience disturbed on a basic,...

The use of ketamine in electroconvulsive therapy.

Psychiatria Polska 2015 K. Kucia, W. Merk

In recent years, data on the possibility of rapid clinical improvement after administration of ketamine in patients diagnosed with depression have been published more frequently. Ketamine, used as an anaesthetic during ECT procedures, despite earlier concerns, has both: a good safety profile and minimal effect on seizure threshold, which is used in cases of non-response to ECT. Postulated...

Effectiveness of ketamine in depressed patients resistant to ECT or rTMS therapy.

Psychiatria Polska February 20, 2014 Paweł Gosek, Magdalena Chojnacka, Łukasz Święcicki et al.

Cel: W ostatnich latach opublikowano wiele opisów dotyczących możliwości uzyskania szybkiej i istotnej klinicznie poprawy stanu psychicznego u pacjentów z rozpoznaniem depresji po podaniu antagonisty receptorów N-metylo-D-asparaginowych (NMDA) - ketaminy. Większość badań dotyczy podania ketaminy pacjentom z depresją lekooporną, co jednak nie oznaczało oporności na leczenie elektrowstrząsowe. W...